{"denoms":[{"counts":[{"groupId":"BG000","value":"29"},{"groupId":"BG001","value":"27"},{"groupId":"BG002","value":"29"},{"groupId":"BG003","value":"28"},{"groupId":"BG004","value":"35"},{"groupId":"BG005","value":"21"},{"groupId":"BG006","value":"10"},{"groupId":"BG007","value":"21"},{"groupId":"BG008","value":"11"},{"groupId":"BG009","value":"11"},{"groupId":"BG010","value":"12"},{"groupId":"BG011","value":"12"},{"groupId":"BG012","value":"8"},{"groupId":"BG013","value":"14"},{"groupId":"BG014","value":"25"},{"groupId":"BG015","value":"10"},{"groupId":"BG016","value":"8"},{"groupId":"BG017","value":"6"},{"groupId":"BG018","value":"12"},{"groupId":"BG019","value":"12"},{"groupId":"BG020","value":"12"},{"groupId":"BG021","value":"12"},{"groupId":"BG022","value":"12"},{"groupId":"BG023","value":"11"},{"groupId":"BG024","value":"6"},{"groupId":"BG025","value":"7"},{"groupId":"BG026","value":"7"},{"groupId":"BG027","value":"408"}],"units":"Participants"}],"groups":[{"description":"During phase 1b participants with Non-Small Cell Lung Cancer (NSCLC) received utomilumab 500 mg intravenously (IV) every 4 weeks (Q4W) with 10 milligrams per kilogram (mg/kg) of avelumab administered IV every 2 weeks (Q2W) for 2 cycles, where each cycle was of 4 weeks.","id":"BG000","title":"Combination A Phase 1b NSCLC: Utomilumab 500 mg + Avelumab"},{"description":"During phase 1b participants with NSCLC received utomilumab 100 mg IV Q4W with 10 mg/kg of avelumab administered IV Q2W for 2 cycles, where each cycle was of 4 weeks.","id":"BG001","title":"Combination A Phase 1b NSCLC: Utomilumab 100 mg + Avelumab"},{"description":"During phase 1b participants with NSCLC received utomilumab 20 mg IV Q4W with 10 mg/kg of avelumab administered IV Q2W for 2 cycles, where each cycle was of 4 weeks.","id":"BG002","title":"Combination A Phase 1b NSCLC: Utomilumab 20 mg + Avelumab"},{"description":"During Phase 2 participants with melanoma received utomilumab 100 mg IV Q4W with 10 mg/kg of avelumab administered IV Q2W for 2 cycles, where each cycle was of 4 weeks.","id":"BG003","title":"Combination A Phase 2 Melanoma: Utomilumab 100 mg + Avelumab"},{"description":"During Phase 2 participants with Squamous Cell Carcinoma of the Head and Neck (SCCHN) received utomilumab 100 mg IV Q4W with 10 mg/kg of avelumab administered IV Q2W for 2 cycles, where each cycle was of 4 weeks.","id":"BG004","title":"Combination A Phase 2 SCCHN: Utomilumab 100 mg + Avelumab"},{"description":"During Phase 2 participants with Triple Negative Breast Cancer (TNBC) received utomilumab 100 mg IV Q4W with 10 mg/kg of avelumab administered IV Q2W for 2 cycles, where each cycle was of 4 weeks.","id":"BG005","title":"Combination A Phase 2 TNBC: Utomilumab 100 mg + Avelumab"},{"description":"During Phase 2 participants with Squamous cell lung cancer (SCLC) received utomilumab 100 mg IV Q4W with 10 mg/kg of avelumab administered IV Q2W for 2 cycles, where each cycle was of 4 weeks.","id":"BG006","title":"Combination A Phase 2 SCLC: Utomilumab 100 mg + Avelumab"},{"description":"During Phase 2 participants with NSCLC received utomilumab 100 mg IV Q4W with 10 mg/kg of avelumab administered IV Q2W for 2 cycles, where each cycle was of 4 weeks.","id":"BG007","title":"Combination A Phase 2 First Line (1L) NSCLC: Utomilumab 100 mg + Avelumab"},{"description":"During Phase 2 participants with NSCLC received utomilumab 100 mg IV Q4W for cycle 1 then utomilumab 100 mg IV Q4W with 10 mg/kg of avelumab administered IV Q2W starting at cycle 2.","id":"BG008","title":"Combination A Phase 2 1L NSCLC: Utomilumab Then Utomilumab + Avelumab"},{"description":"During Phase 2 participants with NSCLC received avelumab 10 mg/kg administered IV Q2W for cycles 1 then utomilumab 100 mg IV Q4W with 10 mg/kg of avelumab administered IV Q2W starting at cycle 2.","id":"BG009","title":"Combination A Phase 2 1L NSCLC: Avelumab Then Utomilumab + Avelumab"},{"description":"During Phase 1b participants received PF-04518600 0.3 mg/kg IV Q2W with 10 mg/kg of avelumab administered IV Q2W. Phase 2 in the melanoma cohort was not planned.","id":"BG010","title":"Combination B Phase 1b: PF-04518600 0.3 mg/kg + Avelumab"},{"description":"During Phase 1b participants received PF-04518600 1.0 mg/kg IV Q2W with 10 mg/kg of avelumab administered IV Q2W. Phase 2 in the melanoma cohort was not planned.","id":"BG011","title":"Combination B Phase 1b: PF-04518600 1.0 mg/kg + Avelumab"},{"description":"During Phase 1b participants received PF-04518600 3.0 mg/kg IV Q2W with 10 mg/kg of avelumab administered IV Q2W. Phase 2 in the melanoma cohort was not planned.","id":"BG012","title":"Combination B Phase 1b: PF-04518600 3.0 mg/kg + Avelumab"},{"description":"During Phase 2 participants with NSCLC received PF-04518600 0.3 mg/kg IV Q2W with 10 mg/kg of avelumab administered IV Q2W.","id":"BG013","title":"Combination B Phase 2 NSCLC: PF-04518600 0.3 mg/kg + Avelumab"},{"description":"During Phase 2 participants with SCCHN received PF-04518600 0.3 mg/kg IV Q2W with 10 mg/kg of avelumab administered IV Q2W.","id":"BG014","title":"Combination B Phase 2 SCCHN: PF-04518600 0.3 mg/kg + Avelumab"},{"description":"During Phase 1b participants received PD 0360324 50 mg IV Q2W with 10 mg/kg of avelumab administered IV Q2W for 2 cycles, where each cycle was of 4 weeks. Phase 2 was not planned.","id":"BG015","title":"Combination C Phase 1b: PD 0360324 50 mg + Avelumab"},{"description":"During Phase 1b participants received PD 0360324 100 mg IV Q2W with 10 mg/kg of avelumab administered IV Q2W for 2 cycles, where each cycle was of 4 weeks.","id":"BG016","title":"Combination C Phase 1b: PD 0360324 100 mg + Avelumab"},{"description":"During Phase 1b participants received PD 0360324 150 mg IV Q2W with 10 mg/kg of avelumab administered IV Q2W for 2 cycles, where each cycle was of 4 weeks.","id":"BG017","title":"Combination C Phase 1b: PD 0360324 150 mg + Avelumab"},{"description":"During Phase 1b participants received utomilumab 20 mg IV Q4W along with PF-04518600 0.1 mg/kg IV Q2W and 10 mg/kg of avelumab administered IV Q2W for 2 cycles, where each cycle was of 4 weeks. Phase 2 was not planned.","id":"BG018","title":"Combination D Phase 1b: Utomilumab 20 mg + PF-04518600 0.1 mg/kg + Avelumab"},{"description":"During Phase 1b participants received utomilumab 50 mg IV Q4W along with PF-04518600 0.1 mg/kg IV Q2W and 10 mg/kg of avelumab administered IV Q2W for 2 cycles, where each cycle was of 4 weeks. Phase 2 was not planned.","id":"BG019","title":"Combination D Phase 1b: Utomilumab 50 mg + PF-04518600 0.1 mg/kg + Avelumab"},{"description":"During Phase 1b participants received utomilumab 20 mg IV Q4W along with PF-04518600 0.3 mg/kg IV Q2W and 10 mg/kg of avelumab administered IV Q2W for 2 cycles, where each cycle was of 4 weeks. Phase 2 was not planned.","id":"BG020","title":"Combination D Phase 1b: Utomilumab 20 mg + PF-04518600 0.3 mg/kg + Avelumab"},{"description":"During Phase 1b participants received utomilumab 50 mg IV Q4W along with PF-04518600 0.3 mg/kg IV Q2W and 10 mg/kg of avelumab administered IV Q2W for 2 cycles, where each cycle was of 4 weeks. Phase 2 was not planned.","id":"BG021","title":"Combination D Phase 1b: Utomilumab 50 mg + PF-04518600 0.3 mg/kg + Avelumab"},{"description":"During Phase 1b participants received utomilumab 20 mg IV Q4W along with PF-04518600 1.0 mg/kg IV Q2W and 10 mg/kg of avelumab administered IV Q2W for 2 cycles, where each cycle was of 4 weeks. Phase 2 was not planned.","id":"BG022","title":"Combination D Phase 1b: Utomilumab 20 mg + PF-04518600 1.0 mg/kg + Avelumab"},{"description":"During Phase 1b participants received utomilumab 50 mg IV Q4W along with PF-04518600 1.0 mg/kg IV Q2W and 10 mg/kg of avelumab administered IV Q2W for 2 cycles, where each cycle was of 4 weeks. Phase 2 was not planned.","id":"BG023","title":"Combination D Phase 1b: Utomilumab 50 mg + PF-04518600 1.0 mg/kg + Avelumab"},{"description":"During Phase 1b participants with SCCHN received CMP-001 at 10 mg for an initial 7 doses (2 sub-cutaneous \\[SC\\] administered at weekly intervals, followed by 5 intra tumoral \\[IT\\] administered at weekly intervals) and then administered IT Q2W for all cohorts along with 10 mg/kg of avelumab administered IV Q2W. Phase 2 was not planned.","id":"BG024","title":"Combination F Phase 1b SCCHN: CMP-001 10 mg + Avelumab"},{"description":"During Phase 1b participants with SCCHN received CMP-001 at 10 mg for an initial 7 doses (2 SC administered at weekly intervals, followed by 5 IT administered at weekly intervals) and then administered IT Q2W for all cohorts along with 10 mg/kg of avelumab administered IV Q2W all cohorts plus utomilumab 100 mg administered IV Q4W. Phase 2 was not planned.","id":"BG025","title":"Combination F Phase 1b SCCHN: CMP-001 10 mg Then Avelumab + Utomilumab 100 mg"},{"description":"During Phase 1b participants with SCCHN received CMP-001 at 10 mg for an initial 7 doses (2 SC administered at weekly intervals, followed by 5 IT administered at weekly intervals) and then administered IT Q2W for all cohorts along with 10 mg/kg of avelumab administered IV Q2W all cohorts plus PF-04518600 at 0.3 mg/kg administered IV Q2W. Phase 2 was not planned.","id":"BG026","title":"Combination F Phase 1b SCCHN: CMP-001 10 mg Then Avelumab + PF-04518600 0.3 mg/kg"},{"description":"Total of all reporting groups","id":"BG027","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"11.22","value":"64.14"},{"groupId":"BG001","spread":"10.85","value":"60.74"},{"groupId":"BG002","spread":"11.81","value":"61.52"},{"groupId":"BG003","spread":"10.82","value":"63.71"},{"groupId":"BG004","spread":"11.80","value":"61.09"},{"groupId":"BG005","spread":"14.59","value":"53.33"},{"groupId":"BG006","spread":"12.74","value":"59.40"},{"groupId":"BG007","spread":"11.05","value":"65.24"},{"groupId":"BG008","spread":"10.05","value":"65.27"},{"groupId":"BG009","spread":"4.06","value":"69.55"},{"groupId":"BG010","spread":"12.55","value":"54.17"},{"groupId":"BG011","spread":"10.68","value":"64.75"},{"groupId":"BG012","spread":"10.39","value":"65.25"},{"groupId":"BG013","spread":"7.15","value":"66.64"},{"groupId":"BG014","spread":"8.12","value":"63.04"},{"groupId":"BG015","spread":"12.57","value":"62.50"},{"groupId":"BG016","spread":"9.32","value":"56.63"},{"groupId":"BG017","spread":"14.60","value":"54.33"},{"groupId":"BG018","spread":"10.65","value":"65.67"},{"groupId":"BG019","spread":"10.89","value":"63.50"},{"groupId":"BG020","spread":"10.29","value":"66.67"},{"groupId":"BG021","spread":"6.56","value":"61.58"},{"groupId":"BG022","spread":"11.29","value":"59.08"},{"groupId":"BG023","spread":"10.54","value":"61.36"},{"groupId":"BG024","spread":"16.29","value":"58.50"},{"groupId":"BG025","spread":"5.27","value":"66.14"},{"groupId":"BG026","spread":"21.63","value":"60.00"},{"groupId":"BG027","spread":"11.45","value":"62.11"}]}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Age, Continuous","unitOfMeasure":"Years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"8"},{"groupId":"BG001","value":"10"},{"groupId":"BG002","value":"15"},{"groupId":"BG003","value":"8"},{"groupId":"BG004","value":"4"},{"groupId":"BG005","value":"21"},{"groupId":"BG006","value":"4"},{"groupId":"BG007","value":"9"},{"groupId":"BG008","value":"5"},{"groupId":"BG009","value":"7"},{"groupId":"BG010","value":"5"},{"groupId":"BG011","value":"7"},{"groupId":"BG012","value":"3"},{"groupId":"BG013","value":"9"},{"groupId":"BG014","value":"3"},{"groupId":"BG015","value":"7"},{"groupId":"BG016","value":"3"},{"groupId":"BG017","value":"1"},{"groupId":"BG018","value":"3"},{"groupId":"BG019","value":"3"},{"groupId":"BG020","value":"6"},{"groupId":"BG021","value":"3"},{"groupId":"BG022","value":"3"},{"groupId":"BG023","value":"1"},{"groupId":"BG024","value":"1"},{"groupId":"BG025","value":"0"},{"groupId":"BG026","value":"0"},{"groupId":"BG027","value":"149"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"21"},{"groupId":"BG001","value":"17"},{"groupId":"BG002","value":"14"},{"groupId":"BG003","value":"20"},{"groupId":"BG004","value":"31"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"6"},{"groupId":"BG007","value":"12"},{"groupId":"BG008","value":"6"},{"groupId":"BG009","value":"4"},{"groupId":"BG010","value":"7"},{"groupId":"BG011","value":"5"},{"groupId":"BG012","value":"5"},{"groupId":"BG013","value":"5"},{"groupId":"BG014","value":"22"},{"groupId":"BG015","value":"3"},{"groupId":"BG016","value":"5"},{"groupId":"BG017","value":"5"},{"groupId":"BG018","value":"9"},{"groupId":"BG019","value":"9"},{"groupId":"BG020","value":"6"},{"groupId":"BG021","value":"9"},{"groupId":"BG022","value":"9"},{"groupId":"BG023","value":"10"},{"groupId":"BG024","value":"5"},{"groupId":"BG025","value":"7"},{"groupId":"BG026","value":"7"},{"groupId":"BG027","value":"259"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"1"},{"groupId":"BG003","value":"2"},{"groupId":"BG004","value":"1"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"2"},{"groupId":"BG007","value":"2"},{"groupId":"BG008","value":"0"},{"groupId":"BG009","value":"0"},{"groupId":"BG010","value":"1"},{"groupId":"BG011","value":"1"},{"groupId":"BG012","value":"0"},{"groupId":"BG013","value":"0"},{"groupId":"BG014","value":"0"},{"groupId":"BG015","value":"1"},{"groupId":"BG016","value":"1"},{"groupId":"BG017","value":"0"},{"groupId":"BG018","value":"2"},{"groupId":"BG019","value":"1"},{"groupId":"BG020","value":"1"},{"groupId":"BG021","value":"0"},{"groupId":"BG022","value":"0"},{"groupId":"BG023","value":"0"},{"groupId":"BG024","value":"0"},{"groupId":"BG025","value":"0"},{"groupId":"BG026","value":"0"},{"groupId":"BG027","value":"18"}],"title":"Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"26"},{"groupId":"BG001","value":"26"},{"groupId":"BG002","value":"27"},{"groupId":"BG003","value":"26"},{"groupId":"BG004","value":"32"},{"groupId":"BG005","value":"19"},{"groupId":"BG006","value":"8"},{"groupId":"BG007","value":"19"},{"groupId":"BG008","value":"11"},{"groupId":"BG009","value":"11"},{"groupId":"BG010","value":"11"},{"groupId":"BG011","value":"11"},{"groupId":"BG012","value":"7"},{"groupId":"BG013","value":"13"},{"groupId":"BG014","value":"25"},{"groupId":"BG015","value":"9"},{"groupId":"BG016","value":"6"},{"groupId":"BG017","value":"6"},{"groupId":"BG018","value":"9"},{"groupId":"BG019","value":"10"},{"groupId":"BG020","value":"11"},{"groupId":"BG021","value":"12"},{"groupId":"BG022","value":"12"},{"groupId":"BG023","value":"11"},{"groupId":"BG024","value":"5"},{"groupId":"BG025","value":"6"},{"groupId":"BG026","value":"7"},{"groupId":"BG027","value":"376"}],"title":"Not Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"1"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"2"},{"groupId":"BG005","value":"2"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"0"},{"groupId":"BG008","value":"0"},{"groupId":"BG009","value":"0"},{"groupId":"BG010","value":"0"},{"groupId":"BG011","value":"0"},{"groupId":"BG012","value":"1"},{"groupId":"BG013","value":"1"},{"groupId":"BG014","value":"0"},{"groupId":"BG015","value":"0"},{"groupId":"BG016","value":"1"},{"groupId":"BG017","value":"0"},{"groupId":"BG018","value":"1"},{"groupId":"BG019","value":"1"},{"groupId":"BG020","value":"0"},{"groupId":"BG021","value":"0"},{"groupId":"BG022","value":"0"},{"groupId":"BG023","value":"0"},{"groupId":"BG024","value":"1"},{"groupId":"BG025","value":"1"},{"groupId":"BG026","value":"0"},{"groupId":"BG027","value":"14"}],"title":"Unknown or Not Reported"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Ethnicity (NIH/OMB)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"1"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"0"},{"groupId":"BG008","value":"0"},{"groupId":"BG009","value":"0"},{"groupId":"BG010","value":"0"},{"groupId":"BG011","value":"0"},{"groupId":"BG012","value":"0"},{"groupId":"BG013","value":"0"},{"groupId":"BG014","value":"0"},{"groupId":"BG015","value":"0"},{"groupId":"BG016","value":"0"},{"groupId":"BG017","value":"0"},{"groupId":"BG018","value":"0"},{"groupId":"BG019","value":"0"},{"groupId":"BG020","value":"0"},{"groupId":"BG021","value":"0"},{"groupId":"BG022","value":"0"},{"groupId":"BG023","value":"0"},{"groupId":"BG024","value":"0"},{"groupId":"BG025","value":"0"},{"groupId":"BG026","value":"0"},{"groupId":"BG027","value":"1"}],"title":"American Indian or Alaska Native"},{"measurements":[{"groupId":"BG000","value":"5"},{"groupId":"BG001","value":"5"},{"groupId":"BG002","value":"7"},{"groupId":"BG003","value":"1"},{"groupId":"BG004","value":"4"},{"groupId":"BG005","value":"3"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"1"},{"groupId":"BG008","value":"3"},{"groupId":"BG009","value":"2"},{"groupId":"BG010","value":"0"},{"groupId":"BG011","value":"0"},{"groupId":"BG012","value":"0"},{"groupId":"BG013","value":"2"},{"groupId":"BG014","value":"1"},{"groupId":"BG015","value":"0"},{"groupId":"BG016","value":"0"},{"groupId":"BG017","value":"1"},{"groupId":"BG018","value":"1"},{"groupId":"BG019","value":"3"},{"groupId":"BG020","value":"2"},{"groupId":"BG021","value":"4"},{"groupId":"BG022","value":"1"},{"groupId":"BG023","value":"0"},{"groupId":"BG024","value":"0"},{"groupId":"BG025","value":"0"},{"groupId":"BG026","value":"0"},{"groupId":"BG027","value":"46"}],"title":"Asian"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"1"},{"groupId":"BG007","value":"0"},{"groupId":"BG008","value":"0"},{"groupId":"BG009","value":"0"},{"groupId":"BG010","value":"0"},{"groupId":"BG011","value":"0"},{"groupId":"BG012","value":"0"},{"groupId":"BG013","value":"0"},{"groupId":"BG014","value":"0"},{"groupId":"BG015","value":"0"},{"groupId":"BG016","value":"0"},{"groupId":"BG017","value":"0"},{"groupId":"BG018","value":"0"},{"groupId":"BG019","value":"0"},{"groupId":"BG020","value":"0"},{"groupId":"BG021","value":"0"},{"groupId":"BG022","value":"0"},{"groupId":"BG023","value":"0"},{"groupId":"BG024","value":"0"},{"groupId":"BG025","value":"0"},{"groupId":"BG026","value":"0"},{"groupId":"BG027","value":"1"}],"title":"Native Hawaiian or Other Pacific Islander"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"1"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"2"},{"groupId":"BG005","value":"6"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"2"},{"groupId":"BG008","value":"1"},{"groupId":"BG009","value":"1"},{"groupId":"BG010","value":"2"},{"groupId":"BG011","value":"2"},{"groupId":"BG012","value":"1"},{"groupId":"BG013","value":"1"},{"groupId":"BG014","value":"0"},{"groupId":"BG015","value":"0"},{"groupId":"BG016","value":"0"},{"groupId":"BG017","value":"1"},{"groupId":"BG018","value":"2"},{"groupId":"BG019","value":"0"},{"groupId":"BG020","value":"0"},{"groupId":"BG021","value":"1"},{"groupId":"BG022","value":"0"},{"groupId":"BG023","value":"0"},{"groupId":"BG024","value":"0"},{"groupId":"BG025","value":"1"},{"groupId":"BG026","value":"3"},{"groupId":"BG027","value":"30"}],"title":"Black or African American"},{"measurements":[{"groupId":"BG000","value":"22"},{"groupId":"BG001","value":"19"},{"groupId":"BG002","value":"21"},{"groupId":"BG003","value":"26"},{"groupId":"BG004","value":"25"},{"groupId":"BG005","value":"10"},{"groupId":"BG006","value":"8"},{"groupId":"BG007","value":"16"},{"groupId":"BG008","value":"6"},{"groupId":"BG009","value":"8"},{"groupId":"BG010","value":"9"},{"groupId":"BG011","value":"8"},{"groupId":"BG012","value":"6"},{"groupId":"BG013","value":"10"},{"groupId":"BG014","value":"23"},{"groupId":"BG015","value":"9"},{"groupId":"BG016","value":"7"},{"groupId":"BG017","value":"4"},{"groupId":"BG018","value":"7"},{"groupId":"BG019","value":"8"},{"groupId":"BG020","value":"10"},{"groupId":"BG021","value":"7"},{"groupId":"BG022","value":"11"},{"groupId":"BG023","value":"11"},{"groupId":"BG024","value":"5"},{"groupId":"BG025","value":"5"},{"groupId":"BG026","value":"4"},{"groupId":"BG027","value":"305"}],"title":"White"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"0"},{"groupId":"BG008","value":"0"},{"groupId":"BG009","value":"0"},{"groupId":"BG010","value":"0"},{"groupId":"BG011","value":"0"},{"groupId":"BG012","value":"0"},{"groupId":"BG013","value":"0"},{"groupId":"BG014","value":"0"},{"groupId":"BG015","value":"0"},{"groupId":"BG016","value":"0"},{"groupId":"BG017","value":"0"},{"groupId":"BG018","value":"0"},{"groupId":"BG019","value":"0"},{"groupId":"BG020","value":"0"},{"groupId":"BG021","value":"0"},{"groupId":"BG022","value":"0"},{"groupId":"BG023","value":"0"},{"groupId":"BG024","value":"0"},{"groupId":"BG025","value":"0"},{"groupId":"BG026","value":"0"},{"groupId":"BG027","value":"0"}],"title":"More than one race"},{"measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"1"},{"groupId":"BG004","value":"3"},{"groupId":"BG005","value":"2"},{"groupId":"BG006","value":"1"},{"groupId":"BG007","value":"2"},{"groupId":"BG008","value":"1"},{"groupId":"BG009","value":"0"},{"groupId":"BG010","value":"1"},{"groupId":"BG011","value":"2"},{"groupId":"BG012","value":"1"},{"groupId":"BG013","value":"1"},{"groupId":"BG014","value":"1"},{"groupId":"BG015","value":"1"},{"groupId":"BG016","value":"1"},{"groupId":"BG017","value":"0"},{"groupId":"BG018","value":"2"},{"groupId":"BG019","value":"1"},{"groupId":"BG020","value":"0"},{"groupId":"BG021","value":"0"},{"groupId":"BG022","value":"0"},{"groupId":"BG023","value":"0"},{"groupId":"BG024","value":"1"},{"groupId":"BG025","value":"1"},{"groupId":"BG026","value":"0"},{"groupId":"BG027","value":"25"}],"title":"Unknown or Not Reported"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Race (NIH/OMB)","unitOfMeasure":"Participants"}],"populationDescription":"The safety analysis set included all participants who received at least one dose of study drug."}